Sarepta Therapeutics (NASDAQ: SRPT) has recently received a number of price target changes and ratings updates:
- 11/12/2026 – Sarepta Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d)”.
- 11/10/2026 – Sarepta Therapeutics was upgraded by Deutsche Bank from “sell” to “hold”. They now have a $18.00 price target on the stock, up from $14.00.
- 11/6/2026 – Sarepta Therapeutics was given a new $18.00 price target by Robert W. Baird.
- 11/6/2026 – Sarepta Therapeutics had its price target raised by Royal Bank Of Canada from $17.00 to $18.00. They now have a “sector perform” rating on the stock.
- 10/28/2026 – Sarepta Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
- 10/13/2026 – Sarepta Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
- 10/8/2026 – Sarepta Therapeutics had its price target lowered by Royal Bank Of Canada from $19.00 to $17.00. They now have a “sector perform” rating on the stock.
- 10/5/2026 – Sarepta Therapeutics was downgraded by Zacks Research from “hold” to “strong sell”.
- 10/5/2026 – Sarepta Therapeutics had its “sell” rating reaffirmed by HC Wainwright. They now have a $5.00 price target on the stock.
- 9/30/2026 – Sarepta Therapeutics had its price target lowered by JPMorgan Chase & Co. from $23.00 to $20.00. They now have a “neutral” rating on the stock.
- 9/28/2026 – Sarepta Therapeutics had its “underperform” rating reaffirmed by Needham & Company LLC.
- 9/24/2026 – Sarepta Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
- 9/23/2026 – Sarepta Therapeutics was upgraded by William Blair to “hold”.
Sarepta Therapeutics Stock Down 5.8%
Shares of Sarepta Therapeutics stock opened at $15.13 on Tuesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.46 and a quick ratio of 2.13. The company has a 50-day moving average of $18.44 and a 200 day moving average of $18.48. The firm has a market cap of $1.62 billion, a price-to-earnings ratio of -11.04, a PEG ratio of 0.38 and a beta of 0.45. Sarepta Therapeutics, Inc. has a 1 year low of $14.68 and a 1 year high of $24.68.
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.08 by $0.05. The business had revenue of $381.35 million for the quarter, compared to analyst estimates of $352.20 million. Sarepta Therapeutics had a negative net margin of 5.86% and a negative return on equity of 0.20%. Sarepta Therapeutics’s quarterly revenue was down 4.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.13) earnings per share. As a group, sell-side analysts anticipate that Sarepta Therapeutics, Inc. will post 3.27 earnings per share for the current fiscal year.
Sarepta Therapeutics is a biotechnology company focused on developing genetic medicines for rare diseases, with an emphasis on Duchenne muscular dystrophy (DMD). Its research includes RNA-based treatments designed to affect how genetic instructions are processed, as well as gene therapy approaches. The company’s DMD medicines include exon-skipping therapies such as eteplirsen (Exondys 51), golodirsen (Vyondys 53) and casimersen (Amondys 45). Each is intended for patients with a specific genetic mutation and works by helping cells produce a shortened form of dystrophin, a protein affected by DMD.
Read More
- Five stocks we like better than Sarepta Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Sarepta Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
